Here are the S-1 registration statements from LB Pharmaceuticals Inc (LBRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc is registering up to 4,778,491 shares of common stock for resale by existing holders. The registration covers 4,723,678 shares held by PIPE investors, including 3,306,571 outstanding shares and 1,417,107 shares issuable upon exercise of pre-funded warrants, plus 54,813 shares issued to Maxim Partners LLC.
The company will not receive proceeds from the resale of these shares, other than the nominal $0.0001 per share exercise price if any pre-funded warrants are exercised for cash. LB Pharmaceuticals is a late-stage biopharmaceutical company focused on LB-102, a lead candidate for schizophrenia, bipolar depression, and adjunctive major depressive disorder.